Concise Review: Exploring Immunomodulatory Features of Mesenchymal Stromal Cells in Humanized Mouse Models  

VERA J. MEHLER 1,2, CHRIS BURNS, MELANIE L. MOORE 3  

Key Words. Humanized mouse • Mesenchymal stem cells • Cell therapy • Immunosuppression • Immunomodulation • Human immune system • Graft versus host disease  

ABSTRACT  

With their immunosuppressive features, human mesenchymal stromal cells (MSCs), sometimes also termed as mesenchymal stem cells, hold great potential as a cell-based therapy for various immune-mediated diseases. Indeed, MSCs have already been approved as a treatment for graft versus host disease. However, contradictory data from clinical trials and lack of conclusive proof of efficacy hinder the progress toward wider clinical use of MSCs and highlight the need for more relevant disease models. Humanized mice are increasingly used as models to study immunemediated disease, as they simulate human immunobiology more closely than conventional murine models. With further advances in their resemblance to human immunobiology, it is very likely that humanized mice will be used more commonly as models to investigate MSCs with regard to their therapeutic safety and their immunomodulatory effect and its underlying mechanisms. Recent studies that explore the immunosuppressive features of MSCs in humanized mouse models will be discussed in this review. Stem Cells 2019;37:298–305  

SIGNIFICANCE STATEMENT  

The immunosuppressive features of mesenchymal stromal cells (MSCs) have been widely demonstrated. However, a more widespread clinical use of MSCs is hampered by contradictory data from clinical trials and an incomplete understanding of the underlying mechanism by which MSCs exert this immunosuppression, resulting in inconclusive proof efficacy. The present review discusses humanized mice as a tool to develop a better understanding of the mode of action of MSCs in mitigating the immune response in an in vivo environment that closely resembles human immunobiology. The goal is that a greater understanding may enable and encourage more studies using humanized mice to investigate the immunomodulatory features of MSCs.  

INTRODUCTION  

Mesenchymal Stromal Cells  

Mesenchymal stromal cells (MSCs) are of mesodermal origin and have self-renewal and multipotent differentiation capacity. They give rise to adipocytes, osteocytes, and chondrocytes and can be derived from various origins, such as the bone marrow (BM), dental pulp, umbilical cord blood (UCB), placenta, and adipose tissue [2]. MSCs have been shown to have regenerative potential and contribute to tissue repair [3]. Besides a somatic origin, MSCs can also be differentiated from pluripotent stem cells (PSCs), including embryonic stem cells and induced PSCs (iPSCs), potentially providing an unlimited source of cells for therapeutic use (reviewed in [4]). MSCs have stimulated great interest because of their immunomodulatory and anti-inflammatory properties (Fig. 1). Specifically, MSCs have been shown to inhibit effector T-cell proliferation, drive induction of regulatory T (Treg) cells [5–7], induce macrophage transformation to an M2 anti-inflammatory phenotype [8], modulate dendritic cell (DC) maturation and functional properties [9–11], directly affect B cell proliferation and maturation [12], and impair natural killer T-cell proliferation [13]. To make MSCs more effective as a cellular therapy, it is important to determine the mechanism(s) by which they exert their immunomodulatory effects. Although much remains unknown, the consensus is that MSCs act through cell-to-cell contact as well as soluble factors, either produced constitutively by MSCs or released by target cells induced by crossstalk with MSCs (reviewed in [1]). Numerous soluble factors have been
associated with MSC-mediated immunomodulation, such as indoleamine 2,3-dioxygenase [14, 15], hepatocyte growth factor, transforming growth factor-β [5], prostaglandin E-2 [16–18], interleukin (IL)-10 [19, 20], IL-6 [11], and monocyte chemoattractant protein-1 [6]. In addition, it has also been suggested that cell-to-cell contact between MSCs and T cells is necessary for MSCs to display their inhibitory effect on T-cell proliferation, cytotoxicity, and the number of antigen-specific T cells [21].

Although the mechanism by which MSCs mediate immunosuppression is still incompletely understood, multiple clinical trials have been initiated, in which adult MSCs have been used as a therapy to treat immune-mediated diseases such as graft versus host disease (GvHD), aplastic anemia, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease [1]. In Canada and New Zealand, clinical trials have resulted in the conditional approval of MSCs for the treatment of steroid-resistant and/or immunosuppressant-resistant acute GvHD (aGvHD) in pediatric patients [22–27]. However, it is not only somatic MSCs that are the subject of current clinical trials. Intriguingly, Cynata Therapeutics Limited is running a first-of-its-kind clinical trial using iPSC-derived MSCs for the treatment of GvHD (http://www.prnewswire.com/news-releases/uk-regulatory-authority-approves-cynata-gvhd-clinical-trial-300329939.html). Despite this interest in MSCs for clinical application, both in vivo studies and potentially contradictory data from clinical trials, have failed to show conclusive proof of efficacy [24, 25], and this may yet hinder the progression of this cell therapy to later clinical phases. There remains both a requirement for better MSC potency assay methods and more comprehensive immune monitoring of treated patients to further understand the mode of action of these cells in vivo [24, 28]. Better models to investigate the mechanisms underlying the immunosuppressive function of MSCs may facilitate the clinical application of MSCs, and humanized mice represent one such improved model. In this review, we introduce and summarize the findings of recent studies that have used the humanized mouse model to explore the immunomodulatory properties of MSCs.

**Humanized Mouse Models**

In general, a humanized mouse is a murine model with a human component. However, most of the models relevant to the study of human immune responses use immunocompromised mice in which the immune system has been reconstituted with human immune cells/immune system (Table 1). Over recent years, increasingly elaborate immunocompromised strains have been developed to achieve higher engraftment rates of human cells. A detailed description of the development of humanized mouse models is beyond the scope of this review.
and has been reviewed elsewhere (reviewed in [29–32]). In brief, one of the first immunodeficient strains to be developed used the severe combined immunodeficiency (SCID) mouse, showing deficiency for immune functions mediated by T and B lymphocytes [33]. Similarly, models of immunodeficiency were also generated based on the use of recombination activating

| Model            | Generation/mice | Advantages                                                                 | Disadvantages                                                                 |
|------------------|-----------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Hu-PBMC          | Irradiation     | • Easy to generate                                                         | • No multilineage hematopoiesis                                                |
|                  |                 | • Engraftment of T cells                                                   | • No primary immune response                                                  |
|                  |                 | • Development of GvHD within a few weeks                                   | • Allows only for short-time experiments                                       |
|                  | Human PBMCs     | • Multilineage hematopoiesis                                               | • T-cell education on murine MHC molecules                                     |
|                  |                 | • Primary immune response                                                  | • Murine MHC-restricted T cells may enter into complex immune interactions with human APCs |
|                  | Human CD34⁺ cells | • Multilineage hematopoiesis                                               | • Challenging to generate                                                     |
|                  |                 | • Primary immune response                                                  | • Requires human fetal tissue                                                 |
|                  | Human fetal liver/thymus fragments | • Maintenance of naive, central memory, and effector memory T cells | • Development of late-onset GvHD                                               |
|                  | Human CD34⁺ cells | • Advantages of the BLT also apply to NeoThy                               | • Inadequate reconstitution of the innate immune system                       |
|                  | Human CD34⁺ cells | • More thymus tissue available allows for ~50-fold more mice per donor compared to BLT | • Neonatal tissue is developmentally more mature                              |
|                  | HLA-A2 transgene | • No T-cell education on human MHC class II molecules                      | • Does not require human fetal tissue                                          |
|                  |                 | • No transgenic expression of other human antigens                         | • Inefficient production of antigen-specific IgG                             |
|                  |                 | • Development of HLA-A2-restricted and antigen-specific cytotoxic T cells  | • Requires human neonatal tissue                                              |
|                  |                 | • Production of all human Ig classes                                       | • Potentially susceptible to GvHD                                               |

Abbreviations: APC, antigen-presenting cells; BLT, bone marrow liver thymus; BRG, BALB/c-Rag2<sup>−/−</sup>/IL2r<sup>γ</sup><sup>−/−</sup>; B6RG, C57BL/6-Rag2<sup>−/−</sup>/IL2r<sup>γ</sup><sup>−/−</sup>; GvHD, graft versus host disease; HLA, human leucocyte antigen; Hu, humanized; Ig, immunoglobulin; MHC, major histocompatibility complex; NBSGW (referred to as NSG-W), NOD.B6.SCID IL2r<sup>γ</sup><sup>−/−</sup>KitW41/W41; NOD, nonobese diabetic; NOG, NODShi.Cg-Prkdc<sup>scid</sup>IL2r<sup>γ</sup><sup>tm1Sug</sup>; NRG, NOD-Rag1<sup>−/−</sup>IL2r<sup>γ</sup><sup>−/−</sup>; NSG, NOD/SCID/IL2r<sup>γ</sup><sup>−/−</sup>; PBMCs, peripheral blood mononuclear cells; SCID, severe combined immunodeficiency.

Table 1. Summary of current humanized mouse models with schematic presentation of the generation
gene (Rag) 1 or 2 knockouts [34]. The next generation of immunocompromised mice, including, for example, the nonobese diabetic (NOD)/SCID/IL2rgnull (NSG), NODShiγc·PrkdckdIl2rgmtm1Sadg, BALB/c-Rag2nullIl2rgnull, C57BL/6-Rag2nullIl2rgnull, and NOD-Rag1nullIl2rgnull models, were generated by introducing multiple genetic manipulations resulting in a multidysfunctional immune system [29,32,35]. To subsequently “humanize” immunocompromised mice, human immune cells, such as peripheral blood mononuclear cells (PBMCs) are injected, resulting in engraftment of human T cells [36]. Immunodeficient mice may also be reconstituted with human CD34+ cells, resulting in development of human B cells, T cells, monocytes, and DCs [37]. However, both these models are limited by the education and selection of human T cells in the murine host thymus. The BM liver thymus (BLT) mouse, conversely, allows for T-cell selection on human major histocompatibility complex (MHC). To generate a BLT mouse, human fetal thymus and liver fragments are implanted under the murine kidney capsule, followed by injection of CD34+ cells, derived from the same fetal liver, which allows for T-cell selection in the implanted autologous human thymus [38]. To circumvent the need to use fetal human tissue, Brown et al. recently developed the NeoThy humanized mouse, in which human neonatal thymus and human CD34+ cells are engrafted into immunocompromised mice [39]. Another strategy for T-cell education on human MHC molecules is based on the use of genetically modified humanized mice that express human leukocyte antigen (HLA) molecules. After reconstitution with human CD34+, these mice show development of HLA-A2-restricted and antigen-specific cytotoxic T cells [40].

Humanized mice have been used in the investigation of many clinical indications, including human-specific viral infections, tumor immunology, transplantation, and autoimmunity (reviewed in [30,41–43]). In the fields of transplantation and immune-mediated conditions, despite the availability of various animal models, results do not always translate to clinical efficacy [43]. This is highlighted by the incomplete mimicry of disease phenotypes by conventional mouse models. For instance, classic mouse models that have been transplanted with thymus fragments from myasthenia gravis (MG) patients do not reproduce clinical weakness, whereas a humanized mouse model transplanted with MG thymus resulted in MG-like symptoms [44]. Equally, a humanized mouse model of pulmonary fibrosis exhibited a more severe disease phenotype than nonhumanized murine models, as a direct result of human immune cells being present in the lungs [45]. The availability of humanized mouse models has enabled a mechanistic investigation of human immune responses and also a more relevant testing approach to therapeutic intervention.

RESULTS AND DISCUSSION

**Humanized Mice as Models to Study the Immunomodulatory Effects of MSCs**

Although in vitro studies have successfully provided important insight into the immunomodulatory features of MSCs [5,8–13], the in vitro environment cannot fully reflect the complexity of a human immune response. In addition, although murine models have been used for investigating the immunosuppressive properties of MSCs in vivo [46,47], there remain fundamental differences between the human and murine immune systems. For example, humans and mice differ in their expression of MHC, cytokines, and costimulatory molecules [48], and more specifically, human MSCs differ in their immunomodulatory mechanisms compared with murine MSCs [49]. These differences highlight the urgent need for models that resemble the human milieu more closely, particularly in the field of immunemediated diseases. To meet this need, humanized mice are increasingly being used as a tool with which to test the safety and efficacy of a range of therapeutic strategies [30]. We present here the application of these models to the evaluation of the therapeutic potential of MSCs.

**Clinical Safety and Efficacy of MSCs**

Prior to the acceptance of MSCs as a viable therapeutic option, there is a requirement to demonstrate whether these cells show efficacy and are safe for clinical use. This safety evaluation would comprise the usual regulatory requirements for any cell therapy, provided by National Regulatory Authorities (https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/; http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000405.jsp&mid=WC0b01ac058002958a).

One of the key considerations is the immune response of the recipient to the graft. MSCs that have been used in the clinic are often of allogeneic origin and therefore retain the potential to elicit an immune response in the recipient. Although MSCs have been suggested to be an immune-privileged cell population, there are some reports that indicate that allogeneic MSCs are immunogenic [50]. In this context, humanized mice are a useful tool for assessing the immunogenicity and safety of MSCs. Furthermore, MSCs derived from different donors/origins have also been shown to vary in their efficacy [25,51,52]. If this is true, then it is clearly important to establish the most appropriate source of MSCs for clinical application, and humanized mice represent an attractive model in which the efficacy of different MSC types can be compared.

Lee et al. have used the NSG mouse model reconstituted with human CD34+ cells (NSG-CD34+) to investigate the immunological safety of allogeneic human MSCs [53]. As MHC molecules are the main mediators of an allogeneic immune response, the expression levels of MHC represent a key component in the potential immunogenicity of a cell. The authors demonstrated that MSCs derived from UCB did not express MHC class II in vitro. Furthermore, coculture with PBMCs induced expression of HLA-G in UCB-MSCs, which is associated with immune tolerance. To confirm these results in vivo, T-cell proliferation and proinflammatory cytokines were quantified in response to the injection of UCB-MSCs versus PBMCs into NSG-CD34+ mice. UCB-MSCs resulted in lower T-cell proliferation and reduced interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and immunoglobulin G (IgG) production, suggesting that allogeneic human UCB-MSCs exhibit reduced immunogenicity.

Another related study compared levels of MHC class II expression between different MSC populations, including MSCs derived from iPSCs, fetuses (IMSCs) and adult BM [54]. No MHC class II expression was detected in any of these MSC populations in the absence of IFN-γ. IFN-γ is a proinflammatory cytokine, naturally present in sites of inflammation and therefore often used to recapitulate an in vivo inflammatory environment. When MSCs were stimulated with IFN-γ, MHC
class II molecules were expressed at minimal levels in iPSC-MSCs as opposed to higher levels in fMSCs and BM-MSCs, which suggests that iPSC-MSCs exhibit low levels of immunogenicity. To test whether iPSC-MSCs are not only safe but also show efficacy in vivo, the authors of this study compared the repair efficacy, survival-rate after transplantation, and effect on inflammation between iPSC-MSCs and BM-MSCs in a humanized NSG-PBMC model of hind limb ischemia [54]. The levels of inflammation in the ischemic limbs were determined by quantifying CD45+ and CD4+ cells in the muscle tissue of the ischemic limbs. In order to trace the cells post-translation, MSCs were labeled with green fluorescent protein (GFP) before being injected intramuscularly into four sites of the thigh of the ischemic hind limbs. The results suggested that human iPSC-MSCs led to less inflammation and a better recovery of hind limb ischemia compared with BM-MSCs. Moreover, quantifying GFP+-MSCs revealed that iPSC-MSCs exhibited higher cell survival than BM-MSCs.

Taken together, these studies show that the humanized mouse can be used as an in vivo model to evaluate the immunological safety of MSCs [53, 54]. Moreover, when used as a specific disease model, such as a model of hind limb ischemia, it allows for an assessment of the efficacy of MSCs as a regenerative therapy [54]. It should be mentioned, however, that Lee et al. recognized the limitations of the NSG-CD34+ model, as there was only a small proportion of mature T cells present after reconstitution. They contributed the prevalence of immature T cells to abnormal thymic selection and therefore emphasized the need for confirmation of their results in a more relevant humanized mouse model, such as the BLT mouse [53].

MSC Therapy as a Treatment in GvHD

Although MSCs have received approval for the indication of aGVHD in some countries [22–27], the data from clinical trials have been ambiguous and have failed to show conclusive proof of efficacy [24, 25]. In addition, it has proven to be challenging to determine the mode of action by which MSCs exercise their immunomodulatory phenotype. To further investigate MSCs as a cellular therapy in GvHD, Tobin et al. administered human MSCs into NSG-PBMC humanized mice, which served as model of GvHD [55]. MSC treatment resulted in the reduction of liver and gut pathology and significantly increased survival of GvHD NSG mice. However, the administration of MSCs did not prevent GvHD development in the longer term, corresponding with data from clinical trials [26, 27]. Furthermore, the study suggests that MSCs exert a direct suppressive effect on donor T-cell proliferation and reduced TNF-α production as the underlying mechanism of MSC immunosuppression in GvHD [55]. Another study that used UCB-MSCs to ameliorate GvHD in NOD/SCID mice (reconstituted with human PBMCs) suggested that multiple doses of UCB-MSC were necessary to prevent the development of GvHD, but MSCs were not effective once GvHD had been fully established [56]. This is in accordance with the conclusion by the authors of the first study, proposing that MSCs mediate a more transient mitigating effect on GvHD development, rather than induction of immune tolerance [55]. Given that these findings are in good agreement with the data from some recent clinical trials, the authors reasonably concluded that the NSG-PBMC GvHD mouse serves as a suitable model to explore the underlying mechanism of MSC immunosuppression, and the potential of MSCs as cellular-based therapy in GvHD. Further reflecting the sometimes-conflicting data from clinical trials, other studies utilizing the humanized NSG-PBMC model to mimic GvHD have found that MSCs are not effective in preventing GvHD, even if MSCs were administered in multiple doses [57, 58]. Although humanized mice offer the advantage of enabling human MSCs and MSC-derived soluble factors to interact with human immune cells, GvHD remains a complex disease. Different sources of MSCs, different routes of administration and doses, as well as variability in patient responsiveness to MSC treatment means that, in addition to more relevant disease models, further efforts to standardize therapeutic approaches will be required to improve the outcomes of studies/clinical trials on GvHD.

MSCs in Transplant Rejection

Traditionally, patients who experience allograft rejection following organ transplantation receive immunosuppressive agents, which can lead to severe side effects, such as the development of opportunistic infections [59]. In light of this, alternative immunosuppressive approaches with less severe adverse effects are being investigated. The administration of MSCs in kidney-transplant patients has been promising in this regard, as it resulted in lower incidence of acute rejection, decreased risk of opportunistic infection, and better graft function [60]. Currently, BM-MSCs are the most commonly used type of MSCs in the clinic [22, 26]; however, BM aspiration is an invasive procedure and so other sources of MSCs, that can be harvested more conveniently and have comparable immunomodulatory efficacy, may represent an alternative to BM-MSCs. Roemeling-van Rhijn et al. compared the immunomodulatory efficacy of BM-MSC and adipose tissue-derived MSCs in the context of a humanized SCID-PBMC mouse, which was engrafted with a human allogeneic skin graft [61]. The skin grafts showed pronounced CD45+ T-cell infiltrates consisting of CD4+ and CD8+ T cells and increased IFN-γ expression, reflecting rejection of the graft. To exclude rejection responses because of xenogeneic recognition, a control group was transplanted with the human skin graft but did not receive an adoptive transfer of human PBMCs. The control mice did not demonstrate leukocyte infiltration, confirming that the graft is recognized as an allograft rather than a xenotransplant. Alloreactivity toward the skin graft was significantly suppressed by both BM-MSCs and adipose tissue-derived MSCs, with similar efficacy. Importantly, this study demonstrated the utility of the humanized SCID-PBMC allograft model for the evaluation of MSC immunosuppressive efficacy in allograft rejection.

In a diabetic NSG-PBMC model, human BM-MSCs were used to mitigate the immune response to human islet transplants [62]. Islet transplantation as a treatment for type 1 diabetes was introduced in the late 1990s; however, its more widespread application was hampered by the availability of islet grafts and also by transplant rejection and the loss of islet viability and function [62]. Wu et al. showed that cotransplantation of human islets with BM-MSCs improved islet allograft survival and significantly prolonged the duration of insulin independence in the humanized mouse model. Addressing the underlying mechanism of transplant tolerance, the authors suggested BM-MSC-mediated activation of monocytes to produce IL-10 and the promotion of Treg cell proliferation through soluble factors.
Although MSCs have been previously shown to improve islet transplantation in vivo [63], the presence of human immune cells in the humanized mouse model led to an improved understanding of the mechanism by which BM-MSCs promote immunomodulation in allograft transplantation.

These studies demonstrate that humanized mouse models primarily offer an in vivo environment that closely represents the human immune milieu. However, they also provide a potential source of “humanized” immune cells and serve as an alternative to invasive sampling of human cells, such as BM, from a human donor. Importantly, easier access to cells of this type may facilitate research in this area. As an example of this, Chen et al. have used BM from the humanized NSG-CD34+ mouse model to obtain human DCs to investigate MSCs and their effects on allograft rejection [64]. On a molecular level, transplant rejection occurs when transplant alloantigens are recognized as “foreign” by the host. There are three known pathways of allorecognition: direct, indirect, and semidirect allorecognition. Although direct allorecognition describes the presentation of donor MHC molecules by donor antigen-presenting cells (APCs) (received by the host in the donor graft), indirect allorecognition involves host APCs presenting donor MHC molecules to host T cells. The semidirect pathway of allorecognition proposes that recipient APCs acquire intact allogeneic MHC-peptide complexes through cell-to-cell contact from donor APCs [65]. All three pathways rely on APCs as key players in the response. As DCs are one of the most important types of APC, they play a crucial role in alloantigen presentation and thus transplant rejection. It has previously been suggested that MSCs have immunomodulatory effects in vitro on human DC differentiation and maturation [9, 10]. Although these reports focused on DCs derived from human PBMCs as well as from human CD34+ cells, the study reported by Chen et al. investigated the effects of MSCs on BM-derived DCs, where the DCs were derived from the BM of the humanized NSG-CD34+ model [64]. To explore the effect of MSCs on DC maturation and differentiation, MSCs were cocultured with the human BM-derived DCs. The study showed that MSCs inhibited DC differentiation and kept DCs in an immature or quiescent state, demonstrated by changes in phenotype and function [64]. The authors conclude by suggesting that inhibition of DC differentiation and maturation may represent one of several potential mechanisms that explain the beneficial effects of MSCs in clinical trials but also highlight the need for confirmation of these results in an in vivo model. Furthermore, this study showed that the humanized NSG-CD34+ model represents an important tool to generate human BM-derived DCs.

MSCs in Other Immune-Mediated Diseases

The immunosuppressive features of MSCs are also being explored for clinical application in various immune-mediated diseases. An example of this is MG, which is a rare autoimmune neuromuscular disease characterized by the presence of anticholinergic receptor (AChR) antibodies. These autoantibodies react against proteins of the neuromuscular junction, which causes fluctuating skeletal muscle weakness and fatigability. To simulate MG in a murine model, Sudres et al. transplanted thymic fragments from MG patients into NSG mice [44]. The NSG-MG mice exhibited MG-like symptoms and displayed mouse anti-human AChR antibody levels correlating with the levels observed in the patient sera. The authors compared the therapeutic efficacy of MSCs isolated from human adipose tissues in a resting state (rMSCs) with the same population of cells in an in vitro preconditioned state (cMSCs). Preconditioning consisted of 3-day in vitro coculture of MSCs with allogeneic PBMCs. The study showed that systemic administration of cMSCs led to an improvement in disease phenotype with decreased MG occurrence and severity in treated mice, and this was much more marked than that seen with rMSCs. Consequently, the authors suggest that preconditioning of MSCs could enhance efficacy and may present a promising strategy for the treatment of MG and potentially other autoimmune diseases. Furthermore, investigation of the mode of action identified that inhibition of cellular proliferation and a reduction in the expression of several molecules of the TNF pathway and costimulatory molecules contributed to the immunosuppression mediated by cMSCs. Importantly, the correlation between each mouse experiment and the respective patient’s MG phenotype suggests that the humanized NSG-MG is a suitable disease model, which can be used to investigate the efficacy and mode of action of MSCs as therapy for MG [44].

The immunomodulatory effects of MSCs have also been investigated for the treatment of pulmonary fibrosis, a condition in which immune cells and their secreted cytokines play a critical role in promoting scarring of lung tissue [66]. Ni et al. established a pulmonary fibrosis humanized mouse model, utilizing Rag2γcβ2L2r/γcβ2L2r−/− mice reconstituted with human PBMCs, which then received an injection of bleomycin to induce pulmonary fibrosis [45]. Importantly, they confirmed that humanized mice exhibited a more severe disease phenotype than murine models and suggested that this is a direct result of human immune cells being present in the lungs. Furthermore, human CD8+ T cells were identified to be critical for the induction of pulmonary fibrosis. Human BM-MSCs injected into these humanized mice resulted in an alleviation of pulmonary fibrosis. The improvement in symptoms was attributed to MSC-mediated modulation of bleomycin-induced abnormal T-cell activation. Furthermore, experiments revealed that the expression of programmed death-ligand 1 by MSCs played a critical role in suppressing pulmonary infiltrating T cells. This study highlights the superiority of humanized mice over alternative murine models, to both mimic pulmonary fibrosis, but also to begin to determine the underlying mechanism of MSC-mediated attenuation of symptoms.

CONCLUSION

Over recent years, the development of humanized mice has led to models that can recapitulate elements of the human immune system. The rapid pace of development of these models may soon permit their use as both preclinical models for a number of immune-mediated diseases and also for the exploration of the mode of action of therapeutic intervention strategies. Although MSCs are being used in the clinic already, the underlying mechanisms of the MSC immunomodulatory effects are far from fully understood. Better understanding of MSC immunobiology is particularly important because results of clinical trials have often been controversial and conclusive proof of efficacy has been lacking [24, 25]. Advances in our understanding may lead to the discovery of new ways to modify MSCs to be therapeutically efficacious. Taken together, it is clear that further progress toward humanized mouse models that most closely mimic human immune biology may be of particular benefit in the clinical translation of the exciting therapeutic potential offered by MSCs.
ACKNOWLEDGMENTS

The production of this review was funded, in part, by a grant from UK Department of Health’s Policy Research Programme, Grant 044/0069. The report is based on independent research commissioned and funded by the NIHR Policy Research Programme, Regulatory Science Research Unit. The views expressed in the publication are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health, “arms” length bodies, or other government departments.

REFERENCES

1. Zhao Q, Ren H, Han Z. Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. J Cell Immunol 2016;2:3–20.
2. Pittenger MF, Mackay AM, Beck SC et al. Multipotential potential of adult human mesenchymal stem cells. Science 1999;284:143–147.
3. Caplan AI. Why are MSCs therapeutic? New data: New insight. J Pathol 2009;217:318–324.
4. Luzzani CD, Miriuka SG. Pluripotent stem cells as a robust source of mesenchymal stem cells. Stem Cell Rep 2017;13:68–78.
5. Di Nicola M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli. Blood 2002;99:3838–3843.
6. Li C-L, Leng Y, Zhao B et al. Human iPSC-MSC-derived xenografts modulate immune responses by inhibiting the cleavage of caspases. Stem Cells 2017;35:1719–1732.
7. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42–48.
8. Abumaree MH, al Jumah MA, Kaloneis B et al. Placental Mesenchymal Stem Cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev Rep 2013;9:620–641.
9. Nauta AJ, Kruisselbrink AB, Lurvink E et al. Mesenchymal stem cells inhibit generation and function of both cd34+– derived and monocyte-derived dendritic cells. J Immunol 2006;177:2080–2087.
10. Zhang W, Ge W, Li C et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004;13:263–271.
11. Djouad F, Charbonnier LM, Bouffi C et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007;25:2025–2032.
12. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367–372.
13. Pignone I, Benvenuto F, Bocca P et al. Reciprocal interactions between human mesenchymal stem cells and γδ T cells or invariant natural killer T cells. Stem Cells 2009;27:693–702.
14. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit alloergic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degragation. Blood 2004;103:4619–4621.
15. Su J, Chen X, Huang V et al. Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ 2014;21:388.
16. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate alloergenic immune cell responses. Blood 2005;105:1815–1822.
17. Rozenberg A, Rezk A, Boivin MN et al. Human mesenchymal stem cells impact Th17 and Th1 responses through a prostaglandin E2 and myeloid-dependent mechanism. Stem Cells Translational Medicine 2016;5:1506–1514.
18. Spaggiari GM, Abdelrazik H, Becchetti F et al. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009;113:6576–6583.
19. Gonzalez-Rey E, Anderson P, Gonzalez MA et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 2009;58:929–939.
20. Kyurkchiev D, Bochev I, Ivanova-Todorova E et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells 2014;6:552–570.
21. Kramerov M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101:3722–3729.
22. Ball LM, Bernardo ME, Roelofs H et al. Multiple infusions of mesenchymal stem cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br J Haematol 2013;163:501–509.
23. Muroi K, Miyamura K, Okada M et al. Bone marrow-derived mesenchymal stem cells (RM-031) for steroid-refractory grade III or IV acute graft-versus-host-disease: A phase II/IIa study. Int J Hematol 2016;103:243–250.
24. Locatelli F, Algeri M, Trevisan V et al. Remestemcel-L for the treatment of graft versus host disease. Expert Rev Clin Immunol 2017;13:43–56.
25. Galipeau J. The mesenchymal stromal cells dilemma—Does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 2013;15:2–8.
26. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579–1586.
27. Martin PJ, Uberti JP, Soffer RJ et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: Results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010;16:S169–S170.
28. de Wolf C, van de Bovenkamp M, Hoefnagel M. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. Cytotherapy 2017;19:784–797.
29. Ito R, Takahashi T, Katano I et al. Current advances in humanized mouse models. Cell Mol Immunol 2012;9:208–214.
30. Yong KSM, Her Z, Chen Q. Humanized mice as unique tools for human-specific studies. Arch Immunol Ther Exp (Warsz) 2018;66:245–266.
31. Shultz LD, Brehm MA, Garcia-Martinez IV et al. Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol 2012;12:786–798.
32. Skelton JK, Ortega-Prieto AM, Dorner M. A Hitchciker’s guide to humanized mice: New pathways to studying viral infections. Immunology 2018;154:50–61.
33. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527–530.
34. Mombauters P, Iacomini J, Johnson RS et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992;68:869–877.
35. Shultz LD, Lyons BL, Burzenski LM et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477–6489.
36. Christianson SW, Greiner DL, Hesselton RA et al. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-SCID mice. J Immunol 1997;158:3578–3586.
37. Brehm MA, Cuthbert A, Yang C et al. Parameters for establishing humanized mouse

AUTHOR CONTRIBUTIONS

V.J.M.: conception and design, manuscript writing; C.J.B.: conception and design, manuscript writing; M.L.M.: conception and design, manuscript writing.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicated no potential conflicts of interest.
models to study human immunity: Analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rynull mutation. Clin Immunol 2010;135:84–98.

38. Lan P, Tocimura N, Shimizu A et al. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006;108:487–492.

39. Brown ME, Zhou Y, McIntosh BE et al. Use of humanized mice to study the pathogenesis of autoimmune and inflammatory diseases. Annu Rev Pathol 2017;12:187–207.

40. Shultz LD, Saito Y, Najima Y et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rnull humanized mice. Proc Natl Acad Sci U S A 2010;107:13022–13027.

41. Kenney LL, Shultz LD, Greiner DL et al. Humanized mouse models for transplant immunology. Am J Transplant 2016;16:389–397.

42. Walsh NC, Kenney LL, Jangalwe S et al. Humanized mouse models of clinical disease. Annu Rev Pathol 2017;12:187–215.

43. Kobozi A, Jones-Hall Y, Valiente FJ et al. Use of humanized mice to study the pathogenesis of autoimmunity and inflammatory diseases. Inflamm Bowel Dis 2015;21:1652–1663.

44. Sudres M, Maurer M, Robinet M et al. Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model. JCI Insight 2017;2:e89665.

45. Ni K, Liu M, Zheng J et al. PD-1/PD-L1 pathway mediates the alleviation of pulmonary fibrosis by human mesenchymal stem cells in humanized mice. Am J Respir Cell Mol Biol 2018;58:684–695.

46. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141–150.

47. García-Castro J et al. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006;24:2582–2591.

48. Metas J, Hughes CC. Of mice and men: differences between mouse and human immunology. J Immunol 2004;172:2731–2738.

49. Su J, Chen X, Huang Y et al. Pathogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ 2014;21:388–396.

50. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: Immune evasive, not immune privileged. Nat Biotechnol 2014;32:252–260.

51. Menard C, Pacelli L, Bassi G et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: Standardization of immune quality controls. Stem Cells Dev 2013;22:1789–1801.

52. Phinney DG. Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy. J Cell Biochem 2012;113:2806–2812.

53. Lee M, Jeong SY, Ha J et al. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo. Biochem Biophys Res Commun 2014;446:983–989.

54. Sun YQ, Zhang Y, Li X et al. Insensitivity of human iPSC cells-derived mesenchymal stem cells to interferon-γ-induced HLA expression potentiates repair efficiency of hind limb ischemia in immune humanized NOD Scid gamma mice. Stem Cells 2015;33:3452–3467.

55. Tobin LM, Healy ME, English K et al. Human mesenchymal stem cells suppress donor CD4+ T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol 2013;172:333–348.

56. Tisato V, Naresh K, Girdlestone J et al. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007;21:992–1999.

57. Bruck F, Belle L, Lechanteur C et al. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy 2013;15:257–273.

58. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: Immune evasive, not immune privileged. Nat Biotechnol 2014;32:252–260.

59. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005;56:23–46.

60. Tan J, Wu W, Xu X et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012;307:1169–1177.

61. Roemeling-van Rhijn M, Khairoun M, Korevaar SS et al. Human bone marrow- and adipose tissue-derived mesenchymal stromal cells are immunosuppressive in vitro and in a humanized allograft rejection model. J Stem Cell Res Ther 2013;Suppl 6:20780.

62. Wu H, Wen D, Mahato RI. Third-party mesenchymal stem cells improved human islet transplantation in a humanized diabetic mouse model. Mol Ther 2013;21:1778–1786.

63. Ding Y, Xu D, Feng G et al. Mesenchymal stem cells prevent the rejection of fully allogeneic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes 2009;58:1797–1806.

64. Chen P, Huang Y, Womer KL. Effects of mesenchymal stem cells on human myeloid dendritic cell differentiation and maturation in a humanized mouse model. J Immunol Methods 2015;427:100–104.

65. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008;13:438–444.

66. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med 2012;18:1028–1040.